辉瑞 CEO 否认会允许在中国生产 Paxlovid 仿制版药，称其不是穷国

 

Vandana Singh

Tue, January 10, 2023 at 5:08 AM PST·1 min read

 

 

In this article:

•  

   

• Albert Bourla

  Greek-American pharmaceutical executive

 

 

• Pfizer Inc (NYSE: PFE) CEO Albert Bourla rebuffed reports saying the company is in talks with Chinese authorities to license a generic version of its Covid-19 treatment Paxlovid.

• Bourla speaking at JPMorgan's healthcare conference, said, "We are not in discussions. We have an agreement already for local manufacturing of Paxlovid in China. So we have a local partner that will make Paxlovid for us, and then we will sell it to the Chinese market."

• Related: New Oral COVID-19 Antiviral Might Be Better Than Pfizer's Paxlovid With Faster Recovery, Fewer Side Effects, Data Shows.

• Bourla said the company shipped thousands of Paxlovid courses in 2022 to China and, in the past couple of weeks, had increased that to millions.

• Concurrently, China's Healthcare Security Administration (NHSA) declined to include Paxlovid in a national reimbursement list that would have allowed patients to get it at a lower price throughout the country.

• Bourla added, "So they want it lower than the lowest of the middle, and we didn't agree. They are the second-highest economy in the world. And I don't think that they should pay less than Salvador, right, which is a poor country"..."We will continue with the private market in China, which is significant."

• Price Action: PFE shares are up 0.10% at $48.44 during the premarket session on the last check Tuesday.